Renal sympathetic denervation improves physical and mental health in resistant hypertension

Renal sympathetic denervation improves anxiety, depression, quality of life and stress in patients with resistant hypertension, according to research presented at ESC Congress 2012 by Dr Denise Fischer from Saarland University Hospital.

Arterial hypertension is often associated with several psychological comorbidities, such as and panic disorders, leading to impaired quality of life. Catheter-based renal sympathetic (RDN) is a novel treatment option for patients with resistant hypertension and has been shown to reduce local and whole-body sympathetic activity and blood pressure (BP).

The aim of the present study was to analyze quality of life, arousal level, anxiety and depression, sleeping quality, intensity of headache and stress tolerance in patients with resistant hypertension before and after RDN.

RDN was performed in 173 patients with resistant hypertension (BP 174/88±23/13mmHg and taking a median of 5 ) aged 63±10 years (53% male). Psychological status, intensity of headache, sleeping quality and were documented before and 3 months after RDN.

Patients rated their physical and mental state and arousal level on a 0-100% scale. Stress was induced by a multi tasking situation (Determination Task) and the total number of correct reactions, omissions and commission errors (responding to stimuli where it is not required) were recorded. Assessments were made of depression and anxiety using the Hospital Scale (HADS) and of quality of life using the Short Form-12 (SF-12). Insomnia and the level of regeneration achieved during sleep were assessed using a 0-100% scale and intensity of headache was measured by a visual analogous scale (VAS).

Three months after RDN was performed, office blood pressure decreased by 17/7 mmHg (p<0.01). In addition patients showed more correct reactions (p<0.0001) and less errors (p<0.05) in the multi tasking situation (Figure A shows the percentile rank (PR) score; the average percentile is 50%). Patients reported improvements in their physical state (from 55.6% to 67.2%; p<0.01), mental state (from 51.6% to 68.4%; p<0.05) and quality of life (p<0.05) (Figure B). Anxiety (p<0.0001) and depression (p<0.0001) scores decreased (Figure C). Arousal level was reduced from 49.9% to 38.9% (p<0.0001).

At baseline 32.2% of patients suffered from sleeping disorders and 60% suffered from headaches. Three months after RDN, sleeping quality improved (p<0.0001) and the intensity of headache decreased (p<0.0001) (Figure D).

"In patients with resistant hypertension overactivity of the sympathetic nervous system causes hyperarousal, leading to higher anxiety and stress levels," said Dr Fischer. "Renal denervation reduces office blood pressure and resting heart rate and does not impair psychological processes."

She added: "Renal denervation may have a positive effect on psychological processes, stress perception and processing as well as quality of life. It improves sleeping quality and may reduce the intensity of headache."

Future research should investigate long term effects of RDN on psychological processes, quality of life, rehospitalisation and mortality rates in a larger cohort of patients.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Timely treatment after stroke is crucial, researchers report

3 hours ago

For years, the mantra of neurologists treating stroke victims has been "time equals brain." That's because getting a patient to the emergency room quickly to receive a drug that dissolves the stroke-causing blood clot can ...

Laughing gas does not increase heart attacks

4 hours ago

(Medical Xpress)—Nitrous oxide—best known as laughing gas—is one of the world's oldest and most widely used anesthetics. Despite its popularity, however, experts have questioned its impact on the risk ...

User comments

More news stories

Validating maps of the brain's resting state

Kick back and shut your eyes. Now stop thinking. You have just put your brain into what neuroscientists call its resting state. What the brain is doing when an individual is not focused on the outside world ...

No danger of cancer through gene therapy virus

In fall 2012, the European Medicines Agency (EMA) approved the modified adeno-associated virus AAV-LPL S447X as the first ever gene therapy for clinical use in the Western world. uniQure, a Dutch biotech company, had developed ...

Antioxidant shows promise in Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.